| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,299,873 ) |
| | 2024 | 2024 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R41HL167404 | HBI-002 for Cystic Fibrosis | 000 | 1 | NIH | 4/10/2024 | $299,975 |
| | 2024 | 2024 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 6 | NIH | 4/10/2024 | $999,898 |
| | 2024 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 000 | 2 | NIH | 12/4/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,299,472 ) |
| | 2023 | 2023 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R41AI164948 | Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | 000 | 2 | NIH | 7/25/2023 | $299,894 |
| | 2023 | 2023 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 5 | NIH | 3/13/2023 | $999,578 |
| | 2023 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 N VERDUGO RD | GLENDALE | CA | 91208-2555 | LOS ANGELES | USA | R41DK123933 | HBI-002 to Treat Ulcerative Colitis | 000 | 2 | NIH | 6/5/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,591,906 ) |
| | 2022 | 2022 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | UG3NS127943 | Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease | 000 | 1 | NIH | 8/5/2022 | $2,111,258 |
| | 2022 | 2022 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41AI164948 | Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | 000 | 1 | NIH | 8/11/2022 | $299,894 |
| | 2022 | 2022 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41NS122576 | HBI-002 to Treat Parkinson?s Disease | 001 | 2 | NIH | 8/22/2022 | $180,754 |
| | 2022 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41NS122576 | HBI-002 to Treat Parkinson?s Disease | 000 | 1 | NIH | 6/3/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $927,639 ) |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 003 | 2 | NIH | 8/10/2021 | $16,896 |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 001 | 1 | NIH | 4/27/2021 | $5,778 |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 002 | 2 | NIH | 8/4/2021 | $76,850 |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41EY033264 | HBI-002 to Treat Diabetic Retinopathy | 000 | 1 | NIH | 8/18/2021 | $299,899 |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41NS122576 | HBI-002 to Treat Parkinson?s Disease | 000 | 1 | NIH | 9/17/2021 | $453,158 |
| | 2021 | 2021 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41DK123933 | HBI-002 to Treat Ulcerative Colitis | 000 | 2 | NIH | 4/28/2021 | $75,058 |
| | 2021 | 2020 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 000 | 1 | NIH | 4/8/2021 | $0 |
| | 2021 | 2019 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43GM125430 | HBI-002 to Treat Traumatic Injury | 000 | 2 | NIH | 2/6/2021 | $0 |
| | 2021 | 2019 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 4 | NIH | 6/17/2021 | $0 |
| | 2021 | 2017 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44DK111260 | HBI-002 to Treat Delayed Graft Function in Kidney Transplant | 000 | 2 | NIH | 2/21/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $441,450 ) |
| | 2020 | 2020 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41DK123933 | HBI-002 to Treat Ulcerative Colitis | 000 | 1 | NIH | 5/15/2020 | $219,112 |
| | 2020 | 2020 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R41HL150889 | HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | 000 | 1 | NIH | 8/9/2020 | $222,338 |
|
| Issue Date FY: 2019 ( Subtotal = $758,886 ) |
| | 2019 | 2019 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 001 | 4 | NIH | 7/23/2019 | $702,410 |
| | 2019 | 2019 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43GM125430 | HBI-002 to Treat Traumatic Injury | 000 | 2 | NIH | 3/12/2019 | $56,476 |
| | 2019 | 2018 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 3 | NIH | 12/18/2018 | $0 |
| | 2019 | 2017 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44DK111260 | HBI-002 to Treat Delayed Graft Function in Kidney Transplant | 000 | 2 | NIH | 8/5/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,438,761 ) |
| | 2018 | 2018 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43GM125430 | HBI-002 to Treat Traumatic Injury | 000 | 1 | NIH | 3/2/2018 | $168,464 |
| | 2018 | 2018 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44HL131065 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 3 | NIH | 9/20/2018 | $1,270,298 |
| | 2018 | 2017 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43HL131065 | Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 2 | NIH | 5/9/2018 | -$1 |
| | 2018 | 2016 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43NS093677 | Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke | 000 | 2 | NIH | 5/23/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $676,584 ) |
| | 2017 | 2017 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R43HL131065 | Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 2 | NIH | 3/22/2017 | $41,551 |
| | 2017 | 2017 | HILLHURST BIOPHARMACEUTICALS, INC. | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020-1626 | LOS ANGELES | USA | R44DK111260 | HBI-002 to Treat Delayed Graft Function in Kidney Transplant | 000 | 2 | NIH | 7/17/2017 | $635,033 |
|
| Issue Date FY: 2016 ( Subtotal = $1,344,696 ) |
| | 2016 | 2016 | HILLHURST BIOPHARMACEUTICALS INC | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020 | LOS ANGELES | USA | R43NS093677 | Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke | 000 | 2 | NIH | 8/19/2016 | $223,821 |
| | 2016 | 2016 | HILLHURST BIOPHARMACEUTICALS INC | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020 | LOS ANGELES | USA | R44DK111260 | HBI-002 to Treat Delayed Graft Function in Kidney Transplant | 000 | 1 | NIH | 8/11/2016 | $862,618 |
| | 2016 | 2016 | HILLHURST BIOPHARMACEUTICALS INC | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020 | LOS ANGELES | USA | R43HL131065 | Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | 000 | 1 | NIH | 4/7/2016 | $258,257 |
|
| Issue Date FY: 2015 ( Subtotal = $475,519 ) |
| | 2015 | 2015 | HILLHURST BIOPHARMACEUTICALS INC | 2029 VERDUGO BLVD #125 | MONTROSE | CA | 91020 | LOS ANGELES | USA | R43NS093677 | Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke | 000 | 1 | NIH | 9/4/2015 | $475,519 |
|
|
